OnKure Therapeutics, Inc.
OKUR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001637715
In the last 90 days, OnKure Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 75 institutions reported holding it in 13F filings for Q2 2026, worth $159.4M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.16K in total
- 2
- 13F holdersQ2 2026, +24 vs. previous quarter
- 75
- 13F valueReported value at the end of Q2 2026
- $159.4M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding OKUR, Q2 2026
No superinvestor reported holding OKUR at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by OnKure Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 23, 2026 (view filing)4:54 PM ET | Sep 21 | 2 days | Saccomano Nicholas APresident and CEO | SSaleClass A Common Stock | −87 | $2.97 | −$258.76 | −0.8%11.2K after | |
| Sep 23, 2026 (view filing)4:52 PM ET | Sep 21 | 2 days | Leverone Jason A.Chief Financial Officer | SSaleClass A Common Stock | −302 | $2.97 | −$898.21 | −1.6%18.5K after | |
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Leverone Jason A.Chief Financial Officer | SSaleClass A Common Stock | −303 | $4.40 | −$1.33K | −1.6%18.8K after | |
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Saccomano Nicholas APresident and CEO | SSaleClass A Common Stock | −86 | $4.40 | −$378.4 | −0.8%11.2K after | |
| Mar 24, 2026 (view filing) | Mar 23 | 1 day | Leverone Jason A.Chief Financial Officer | SSaleClass A Common Stock | −301 | $4.16 | −$1.25K | −1.8%16.0K after | |
| Mar 24, 2026 (view filing) | Mar 23 | 1 day | Saccomano Nicholas APresident and CEO | SSaleClass A Common Stock | −86 | $4.16 | −$357.76 | −1.2%7.33K after | |
| Dec 23, 2025 (view filing) | Dec 22 | 1 day | Leverone Jason A.Chief Financial Officer | SSaleClass A Common Stock | −302 | $2.97 | −$896.94 | −1.8%16.3K after | |
| Dec 23, 2025 (view filing) | Dec 22 | 1 day | Saccomano Nicholas APresident and CEO | SSaleClass A Common Stock | −87 | $2.97 | −$258.39 | −1.2%7.42K after | |
| Sep 24, 2025 (view filing) | Sep 22 | 2 days | Leverone Jason A.Chief Financial Officer | SSaleClass A Common Stock | −303 | $2.62 | −$793.86 | −2.3%12.6K after | |
| Sep 24, 2025 (view filing) | Sep 22 | 2 days | Saccomano Nicholas APresident and CEO | SSaleClass A Common Stock | −88 | $2.62 | −$230.56 | −2.4%3.51K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in OnKure Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 3,998,333 | $18.2M | 0.16% | 00.0% | Unchanged |
| BVF Inc | 3,235,778 | $14.8M | 0.38% | +1,256,806+63.5% | Added |
| Acorn Capital Advisors, LLC | 2,839,674 | $12.9M | 3.53% | 00.0% | Unchanged |
| StepStone Group LP | 2,660,612 | $12.1M | 0.56% | 00.0% | Unchanged |
| ADAR1 Capital Management, LLC | 2,238,684 | $10.2M | 0.48% | −196,257−8.1% | Reduced |
| Vivo Capital, LLC | 1,927,710 | $8.79M | 0.80% | 00.0% | Unchanged |
| Vestal Point Capital, LP | 1,825,699 | $8.33M | 0.19% | −14,120−0.8% | Reduced |
| BlackRock, Inc. | 1,499,845 | $6.84M | 0.00% | +1,450,258+2,924.7% | Added |
| Trails Edge Capital Partners, LP | 1,438,456 | $6.56M | 1.04% | +1,438,456 | New |
| Vanguard Capital Management LLC | 1,437,039 | $6.55M | 0.00% | +854,562+146.7% | Added |